A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.

Breast Cancer Res · 2004 · PMC314444 · PMID 14680495

Europe PMC DOI

hedged sentence

0.2300

closest p · 4.6× alpha

0.2300

boldest claim

The sentences

did not reach statistical significanceP = 0.23not close (p > 0.1)

In an analysis restricted to mutation carriers, the contralateral breast cancer risk was lower in BRCA1 / BRCA2 mutation carriers receiving tamoxifen than in those not receiving tamoxifen, although this did not reach statistical significance (risk ratio 0.47, 95% CI 0.14–1.59; P = 0.23).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.